You are here

Tagrisso

AstraZeneca lung cancer drug meets late-stage trial endpoint

AstraZeneca lung cancer drug meets late-stage trial endpoint

Marketwatch

clinical trials

Flag link:

Struggling Clovis to once again chase FDA favor for would-be Tagrisso competitor

Struggling Clovis to once again chase FDA favor for would-be Tagrisso competitor

BioPharma Dive

Clovis Oncology

Flag link:

AstraZeneca's potential lung cancer blockbuster nabs EU approval

AstraZeneca's potential lung cancer blockbuster nabs EU approval

BioPharma Dive

Flag link:

AstraZeneca chief chalks up milestones on his map to $45B

AstraZeneca chief chalks up milestones on his map to $45B

Fierce Pharma

Flag link:

[video]Top FDA Drug Approvals in 2015: Lung Cancer

[video]Top FDA Drug Approvals in 2015: Lung Cancer

Motley Fool

Flag link:

Clovis Oncology's Loss Could Be a Win for AstraZeneca

Clovis Oncology's Loss Could Be a Win for AstraZeneca

Motley Fool

Clovis Oncology

non-small cell lung cancer

Flag link:

In major victory, AstraZeneca wins FDA approval for potential $3B lung cancer med

In major victory, AstraZeneca wins FDA approval for potential $3B lung cancer med

BioPharma Dive

non-small cell lung cancer

Flag link:

Pages